Novum Opens a New Research Clinic in Fargo, North Dakota

Novum Opens a New Research Clinic in Fargo, North Dakota

FARGO, N.D. -- Novum Pharmaceutical Research Services, a leading contract research organization (CRO) serving the pharmaceutical industry in Phase I-IV clinical trials and related services, announced today that it is opening a new clinical facility in Fargo, North Dakota.  Novum's Fargo site will begin recruiting study participants this month and conduct research studies starting in November, 2013.

Novum is opening the Fargo clinic to accommodate its growth and to continue meeting its clients' needs and timelines.  "Fargo represents the perfect opportunity for Novum and our clients, providing us with added capacity, committed study participants, and a strong local team of clinical and scientific talent," said Christopher H. Chamberlain, Novum's Chief Executive Officer.

The Fargo clinic will open with a strong focus in dermal and transdermal research, building upon Novum's decades of experience in these areas. In 2014, Novum will continue to add early phase research services in Fargo as it also broadens its offerings across all Novum sites, including its clinics in Las Vegas NV, Houston TX, and Pittsburgh PA.

Earlier this year, Novum announced that Alan Copa, Pharm.D., joined Novum's leadership team to oversee its Early Phase expansion, which includes the new Fargo site.  "This is an exciting time for Novum," Copa said. "Novum's Fargo clinic will operate with the high standards of safety, quality, and integrity that our clients have come to expect", he added. The Fargo clinic will operate under Novum's existing standard operating procedures to ensure consistency across the company's Early Phase sites.  

About Novum PRS 
Novum is a contract research organization ("CRO") that provides Phase I through IV clinical research, data management, statistical and reporting services to the pharmaceutical and related industries.  Founded in 1972, it operates Early Phase research facilities in four U.S. locations.  Novum's Clinical Trial Management group conducts Phase II through IV clinical endpoint studies requiring large patient numbers across numerous therapeutic areas.  Please visit http://www.novumprs.com for more information.

NOTE TO EDITORS: A news release announcing Alan Copa joining Novum can be found at: http://tinyurl.com/o39xqzk

CONTACT: Gabrielle Proffitt, Marketing Manager, Novum Pharmaceutical Research Services, 5900 Penn Avenue, Pittsburgh, PA 15206-3817, Phone: 412.362.3300 ext. 587

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Galapagos is selling off its contract research organization Fidelta for $37 million to Polish life science company Selvita.

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.